HaoSi Bio Secures Hundreds of Millions of RMB in Series B Financing to Strengthen Leadership in Clinical Mass Spectrometry
Leading Provider of Integrated Clinical Mass Spectrometry Testing Solutions—Beijing Haosi Biotechnology Co., Ltd. (hereinafter referred to as “Haosi Biotech” or the “Company”) announced today the completion of its Series B financing round, amounting to hundreds of millions of RMB. The round was co-led by Sino-Ocean Capital and Qianhai Fund of Funds, with participation from Huiyuan Capital. Existing shareholders, including Volcanic Stone Capital and Wosheng Investment, continued to increase their investments. China Renaissance served as the exclusive financial advisor to Haosi Biotech in this transaction.
This round of financing will be primarily used for the research and development of the company’s clinical mass spectrometry testing products, accelerate the registration and certification processes for Class II and Class III assay kits as well as its independently developed mass spectrometers, recruit high-caliber technical talent, enhance third-party laboratory testing services, expand the marketing network, intensify market promotion efforts, and consolidate the company’s leading position in the field of clinical mass spectrometry.
Beijing Haosi Biotechnology Co., Ltd., established in 2016, is the first company in China to achieve a breakthrough from scratch in developing mass spectrometry diagnostic kits across multiple disease areas. Leveraging its extensive industry-academia-research expertise in the field of mass spectrometry-based in vitro diagnostics, the company has independently developed a series of clinical mass spectrometry testing products that are pioneering both domestically and globally. These include diagnostic solutions for major diseases such as Alzheimer’s disease (AD), cardiovascular diseases, and urological disorders. Notably, its technology for the early diagnosis and monitoring of Alzheimer’s disease has reached an internationally leading level, holding significant importance for both early detection and clinical treatment phases.
The Company’s reagent product portfolio adopts a combination of “proprietary testing products + routine testing products,” coupled with a market promotion model centered on “in vitro diagnostic (IVD) kits as the primary focus, supplemented by third-party clinical laboratories.” While aggressively pursuing regulatory approvals for multiple pipeline reagent kits, the Company leverages its third-party testing laboratories in Beijing, Sichuan, and Jiangsu to process referred samples from customers across China, thereby comprehensively meeting all clinical needs.
The Haosi-Westlake Precision Medicine Center, jointly established by Haosi Biotechnology and Westlake University, has been officially launched in Kunshan. Adopting a novel model for scientific research commercialization, the project has recruited top global scholars in protein metabolomics to build a world-class mass spectrometry technology platform. As a shareholder of Jiangsu Haosi Biotechnology, Westlake University implements a “full-platform openness” policy, fostering close collaboration and integrating complementary strengths. This partnership leverages scientific research capabilities to accelerate the translation of outcomes and uses internationally leading technologies to drive the iteration of domestic technologies. It is reported that the project will establish industrial centers dedicated to biomolecular mass spectrometry R&D, precision medicine laboratories, and Haosi’s national marketing operations.Furthermore, the company maintains deep collaborative relationships with top-tier research institutions, including the Mayo Clinic platform in the United States, the Mass Spectrometry Research Group at Tsinghua University, Peking University, and the Medical University of Vienna. By vigorously integrating advanced technological resources both domestically and internationally, the company aims to construct an internationally leading mass spectrometry diagnostic platform. Simultaneously, the company is actively strategizing across the upstream and downstream segments of the mass spectrometry industry, aiming to provide comprehensive, end-to-end solutions for clinical mass spectrometry. In terms of hardware, unlike the complete unit OEM approach commonly adopted by other players in the industry, the company sources directly from upstream raw materials to create a fully domestically produced instrument platform, with costs significantly lower than those of existing mass spectrometers on the market.
The company is committed to simplifying and popularizing mass spectrometry testing. It aims not only to apply mass spectrometry technology to meet a broader range of clinical needs but also to introduce mature Western testing assays and technologies into China’s healthcare system. Meanwhile, leveraging the vast number of clinical cases in China, the company will expand its independent research and development and innovation into wider fields.
Dr. Li Lin, Founder and CEO of Haosi Biotechnology, stated, “We are deeply honored to receive recognition and support from renowned domestic investment institutions and our existing shareholders. Clinical mass spectrometry boasts broad application potential, capable of replacing traditional methodologies across multiple fields, including biochemistry, immunology, microbiology, and molecular diagnostics. The market opportunity for our proprietary products exceeds RMB 100 billion, significantly surpassing that of conventional diagnostic products. Moving forward, we will continue to uphold our mission of ‘making mass spectrometry testing accessible,’ strengthen our R&D technology platform, accelerate the commercialization of our products, and serve public health.”
Wei Shihan, Managing Director of Ocean Capital, stated, “In the context of precision medicine, mass spectrometry testing holds immense market potential due to its superior sensitivity, specificity, and accuracy compared to traditional diagnostic technologies, as well as its advantages in high throughput, high efficiency, and low cost. As the first biotechnology company in China to propose a dedicated focus on clinical mass spectrometry solutions, Haosi Biotechnology boasts a diverse product portfolio with differentiated competitive advantages, indicating significant potential for future growth.”
Duan Xufang, Executive Director of Qianhai Fund of Funds, stated, “In the clinical application of mass spectrometry, we have consistently focused on companies with genuine innovative capabilities. Beijing Haosi Biotechnology Co., Ltd. possesses robust scientific research capabilities and has achieved comprehensive, multi-dimensional success in product R&D and commercialization, market positioning, and commercial promotion, thereby establishing significant competitive barriers. We are optimistic about the company’s business model, which offers an all-encompassing solution integrating products and services, and we look forward to more milestone achievements following this round of financing.”
Zhang Shanshan, President of Huiyuan Capital, stated, “The domestic clinical mass spectrometry testing market holds immense potential and is one of the sectors we have long monitored. With its diverse high-quality products, efficient commercial promotion, and the team’s profound expertise in this field, Haosi Biotechnology will continue to deliver superior clinical mass spectrometry applications to patients and the market. Our industrial resources share significant synergistic value with Haosi Biotechnology. Leveraging this opportunity, both parties will collaborate closely to fully support the company in achieving leapfrog development goals. We are firmly confident in the company’s long-term leading position in China’s clinical mass spectrometry sector.”
Hu Minjie, Executive Director of China Renaissance Capital, the investment banking advisor for this transaction, stated: “Haosi Biotechnology is a leader in the field of clinical mass spectrometry applications in China. The company’s diagnostic kits are widely applicable to major disease areas, including cardiovascular and cerebrovascular diseases, urology, and maternal and child health—all of which are key sectors of focus and strategic investment for China Renaissance Capital. We are pleased to have assisted the company in completing this round of financing and look forward to seeing it accelerate the development of its product pipeline post-financing, thereby benefiting more patients.”
Sino-Ocean Capital was established in February 2013 as a professional institution specializing in alternative asset management. Its business scope includes real estate investment, debt investment, equity investment, investment advisory, strategic investment, and other related activities. Adhering to the principles of prudence, responsibility, collaboration, and empowerment in alternative asset management, Sino-Ocean Capital leverages its unique investment insights and value discovery capabilities. Through a full-cycle asset management model encompassing fundraising, investment, management, and exit, along with industrial synergy, it helps partners enhance value, ensures effective management of entrusted funds, and fosters co-creation and shared success, ultimately delivering value to shareholders and society.
Established in 2016 with a scale of RMB 28.5 billion, Qianhai Fund of Funds (FOF) is currently the largest commercially raised fund of funds and a leading private equity investment fund in China. It places equal emphasis on fund investments and direct equity investments, and is managed by Qianhai Ark Asset Management Co., Ltd., led by Jin Haitao, a pioneering figure in China’s venture capital industry. Since its inception, Qianhai FOF has cumulatively invested in 1,300 direct and indirect equity projects, with more than 54 portfolio companies listed on stock exchanges both domestically and internationally.
Huiyuan Capital, established in 2019, is an emerging healthcare investment firm with strong industry roots, jointly founded by a professional investment team and state-owned capital. It has built in-depth collaborative relationships with multiple industry partners and adheres to the investment strategy of “industry empowerment + capital support,” aiming to deliver long-term, stable investment returns to its investors.
Volcanic Stone Capital was established in 2016, dedicated to discovering, investing in, and serving high-growth-potential startups in the fields of China’s internet innovation, pan-intelligent technologies, and new medical health. It provides sustained value-added services to grow alongside these companies. As a professional venture capital fund with a global perspective, it delivers superior returns to its investors.
Wosheng Investment is a fund focused on early- and mid-stage investment opportunities in the biopharmaceutical sector. Technology-driven, the firm is fully committed to helping top-tier scientists and R&D teams achieve success. It has already invested in multiple star enterprises in both China and the United States. With deep expertise in technologies such as gene editing and multi-omics, Wosheng Investment has built a portfolio that includes companies founded by internationally renowned scientists and serial entrepreneurs in the fields of innovative drugs and therapies, as well as diagnostic testing.